TipRanks
Moderna (MX:MRNA)
:MRNA
Mexico Market

Moderna (MRNA) Drug Pipeline

1 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Mrna-1345, Mrna-1365
Respiratory Syncytial Virus (Rsv), Human Metapneuomovirus (Hmpv)
Phase I
Not Yet Recruiting
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
Aug 10, 2026
Mrna-1469
Ebola-Bundibugyo Virus Disease (Ebola-Bdbv)
Phase I
Not Yet Recruiting
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
Jul 27, 2026
Mrna-1982
Lyme Disease
Phase II
Active Not Recruiting
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
Apr 24, 2026
Intismeran, Pembrolizumab Coformulated With Berahyaluronidase Alfa, Mrna-4157, V940
Non-small Cell Lung Cancer
Phase III
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Apr 01, 2026
Mrna-1018-H5
Influenza
Phase III
Active Not Recruiting
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
Mar 22, 2026
Mrna-1273, Mrna-1283, Mrna-1283.222, Mrna-1273.222, Mrna-1283.815, Mrna-1273.815, Mrna-1283.211, Mrna-1283.529, Mrna-1283.251 Variant-Containing Formulation
Sars-Cov-2
Phase IV
Recruiting
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
Nov 25, 2025
Carboplatin, Pembrolizumab, Paclitaxel, Nab-Paclitaxel, Intismeran Autogene, V940, Keytruda, Mrna-4157
Squamous Non-Small Cell Lung Cancer
Phase II
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Oct 24, 2025
Mrna-2808
Relapsed Or Refractory Multiple Myeloma
Phase I/II
Recruiting
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Aug 07, 2025
Mrna-1345
Respiratory Syncytial Virus
Phase III
Active Not Recruiting
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
Aug 05, 2025
Mrna-4106, Nivolumab/Relatlimab
Advanced Solid Tumors
Phase I
Active Not Recruiting
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
Mar 11, 2025

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Moderna (MRNA) have in its pipeline
      MRNA is currently developing the following drugs: Mrna-1345, Mrna-1365, Mrna-1469, Mrna-1982. These drug candidates are in various stages of clinical development as the company works toward FDA approval.